Beyond Air reports $59.4M net loss for FY2023; secures $40M debt facility

Beyond Air, Inc.

GAAP net loss of $59.4M ($55.8M attributable, $1.86 per share) vs $43.2M ($1.68) prior year.
Cash, cash equivalents and marketable securities of $45.9M as of March 31, 2023.
Secured up to $40M debt financing from Avenue Capital; $17.5M funded at 12% or Prime+3.75% with warrants.
Completed phase 1 of LungFit PH commercial launch; shifted to phase 2; CE Mark and FDA label expansion expected in 2023.
Licensed nNOS inhibitors from Hebrew University for autism; first-in-human study planned in 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Beyond Air, Inc. reported financial results for fourth fiscal quarter and year ended March 31, 2023.

Period: fourth fiscal quarter and year ended March 31, 2023
Result: reported results

Exact text from the filing

On June 22, 2023, Beyond Air, Inc. (the “Company”) issued a press release announcing financial results for its fourth fiscal quarter and year ended March 31, 2023.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Beyond Air, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-022243

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.